The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy ...

Shortly after that, the CDC overhauled its vaccine recommendations in COVID, nixing its endorsement of the shots for pregnant women and healthy children. At the time, RFK Jr. said he “couldn’t be more ...

This fall, it may not be possible for many parents to have a healthy child younger than age 5 immunized against COVID.

A Food and Drug Administration official who stepped down less than two weeks ago is getting his job back as the agency's top ...

At the U.S. Food and Drug Administration's (FDA) request, Vinay Prasad is returning to the role of director of the Center for ...

In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related ...

Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Novavax Inc. (NVAX) on Wednesday said that the postmarketing commitment study for its COVID-19 vaccine Nuvaxovid will not ...

Novavax (NVAX) stock gains as the company beats Q2 revenue estimates and raises its 2025 revenue outlook, buoyed by ...

Novavax’s vaccine is the only protein-based coronavirus vaccine available in the U.S. Moderna’s vaccine is an updated, lower-dose version of its existing mRNA-based vaccine.

Novavax had applied for a license for its shot to prevent COVID-19 for anyone over 12 years old, effectively converting it to a traditional approval from the emergency use authorizations the FDA ...